This is not a paywall.

Register for free to continue reading.

The news sucks. But your reading experience doesn't have to. Help us improve that for you by registering for free.

Please create a password or click to receive a login link.

Please enter your password or get a login link if you’ve forgotten

Open Sesame! Thanks for registering.

First Thing, Daily Maverick's flagship newsletter

Join the 230 000 South Africans who read First Thing newsletter.

We'd like our readers to start paying for Daily Maverick

More specifically, we'd like those who can afford to pay to start paying. What it comes down to is whether or not you value Daily Maverick. Think of us in terms of your daily cappuccino from your favourite coffee shop. It costs around R35. That’s R1,050 per month on frothy milk. Don’t get us wrong, we’re almost exclusively fuelled by coffee. BUT maybe R200 of that R1,050 could go to the journalism that’s fighting for the country?

We don’t dictate how much we’d like our readers to contribute. After all, how much you value our work is subjective (and frankly, every amount helps). At R200, you get it back in Uber Eats and ride vouchers every month, but that’s just a suggestion. A little less than a week’s worth of cappuccinos.

We can't survive on hope and our own determination. Our country is going to be considerably worse off if we don’t have a strong, sustainable news media. If you’re rejigging your budgets, and it comes to choosing between frothy milk and Daily Maverick, we hope you might reconsider that cappuccino.

We need your help. And we’re not ashamed to ask for it.

Our mission is to Defend Truth. Join Maverick Insider.

Support Daily Maverick→
Payment options

Mediclinic board rejects Remgro consortium's takeover o...

Business Maverick


Mediclinic board rejects Remgro consortium’s offer to scoop the ‘prize’

(Image: Adobe Stock | Remgro logo)

The announcement on Wednesday of Remgro consortium's offer to buy out Mediclinic has the market buzzing with speculation that the diversified investment holdings company is finally ready to restructure.

Three weeks ago, Remgro and the Mediterranean Shipping Company – acting together as a 50-50 consortium – presented a cash offer to buy Mediclinic at 463 pence a share, which works out to roughly £3.4-billion (R66-billion).  

However, the offer was rejected out of hand by the Mediclinic board as it felt that it “significantly undervalued Mediclinic and its future prospects”. 

According to Simply Wall St, Mediclinic is currently 27.4% undervalued, trading at £4.25 rather than Simply Wall St’s fair value estimate of £5.85. 

Mediclinic’s earnings are forecast to grow 14% year on year, and it posted group revenue of £3.2-billion for the year to March 2022. 

The hospital group currently operates in Switzerland (47% of revenue), southern Africa (28% of revenue) and the United Arab Emirates (25% of revenue). 

The Remgro consortium says if it makes any offer, it will likely be solely cash, and reserved its right to make an offer at any time for a lower value or on less favourable terms. 

Anthony Clark, an analyst at Smalltalkdaily Research, says now that Remgro has shown its hand, it’s clear that it is on a continuing path of cleaning up its portfolio, which includes minority stakes in a number of industries. 

“Mediclinic is a much larger asset and the fact that they want to delist Mediclinic, together with a consortium, clearly indicates that they have a desire to clean up their portfolio and take many of their interests in-house, leading to a better valuation for Remgro,” he says. 

Clark says he would be unsurprised to see Remgro coming back with a higher offer to potentially scoop the Mediclinic “prize”. 

“If they do manage to acquire Mediclinic, that would take a significant proportion of their cash resources, which leads to another question. 

“Might Remgro then, in due course, restructure RCL Foods and take RCL private, and meld their edible oils business into a greater RCL unlisted asset? It’s very intriguing. 

“Things usually move slowly at Remgro, but when they do move, they move with momentum, so perhaps the Mediclinic transaction is part of a wider restructuring of Remgro that the market has been anticipating for a number of years,” he notes. 

If a third party decides to make an offer – or make known a firm intention to make an offer on less favourable terms – the Remgro consortium has also reserved its right to reduce its offer by the amount of any dividend paid or payable to shareholders after 9 June. 

Remgro has until 5pm on 7 July to either announce a firm intention to make an offer or announce that it will not be making another offer. BM/DM



Comments - share your knowledge and experience

Please note you must be a Maverick Insider to comment. Sign up here or sign in if you are already an Insider.

Everybody has an opinion but not everyone has the knowledge and the experience to contribute meaningfully to a discussion. That’s what we want from our members. Help us learn with your expertise and insights on articles that we publish. We encourage different, respectful viewpoints to further our understanding of the world. View our comments policy here.

No Comments, yet

Please peer review 3 community comments before your comment can be posted